Business development activities
Business development at MIPS encompasses the ideas, strategies, and activities that contribute to improving the way we engage in pre-commercial drug development and interactions with commercial groups.
Who we are
Contact us for more information about our business development activities.
Our success stories
COVID-19 mRNA vaccine
Led by Professor Colin Pouton, Dr Harry Al-Wassiti
Allopregnanolone prodrug
Led by Professor Chris Porter, Associate Professor Natalie Trevaskis, in partnership with PureTech Health plc.
QPX9003 antibiotic
Led by Professor Jian Li, Associate Professor Tony Velkov, Dr Kade Roberts, Professor Roger Nation, Professor Philip Thompson, in collaboration with Qpex Biopharma Inc.
β blockade in cancer metastasis
Led by Professor Erica Sloan.
Intranasal heparin in treating COVID-19
A multi-institute project. Led by Professor Michelle McIntosh.
Inhaled oxytocin project
Led by Professor Michelle McIntosh, Peter Lambert.
Ankere Therapeutics
Developing new pharmaceutical agents that target inflammatory conditions, particularly those of the lung.
Phrenix Therapeutics
Developing new therapeutics for cognitive disorders, particularly in schizophrenia.
OmegaOne Therapeutics
Developing a method to block inflammation caused by a number of common diseases, including cardiovascular disease, Parkinson’s, type 2 diabetes and severe asthma.
Celesta Therapeutics
Data science and technology development for unmet medical needs.
Septerna
Discovering and advancing novel small molecule medicines targeting G protein-coupled receptors.
Inosi Therapeutics
Developing therapies to address fibrosis.
Cincera
Developing therapies for metabolic syndrome and type-2 diabetes-related diseases.